IRAK-1/4 Inhibitor

• CAT Number: I003813
• CAS Number: 509093-47-4
• Molecular Formula: C₂₀H₂₁N₅O
• Molecular Weight: 395.41
• Purity: ≥95%
• Synonyms: IRAK-1/4 Inhibitor I; Benzamide, N-[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-2-yl]-3-nitro-
• Target: IRAK
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 200 nM
• IUPAC Name: N-[1-(2-morpholin-4-ylethyl)benzimidazol-2-yl]-3-nitrobenzamide
• InChI: InChI=1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)
• InChIKey: QTCFYQHZJIIHBS-UHFFFAOYSA-N
• SMILES: C1COCCN1CCN2C3=CC=CC=C3N=C2NC(=O)C4=CC(=CC=C4)[N+](=O)[O-]

IRAK-1-4 Inhibitor I(CAT: I003813) is a potent inhibitor of interleukin-1 receptor-associated kinase (IRAK), with IC₅₀ values of 0.3 µM for IRAK-1 and 0.2 µM for IRAK-4. It selectively targets these kinases, which are critical mediators in the Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways. By suppressing IRAK activity, it disrupts downstream signaling events, including the activation of NF-κB and MAPK pathways, reducing the production of pro-inflammatory cytokines. This compound is widely used in immunology research to study inflammatory and autoimmune diseases. Its high potency and specificity make it ideal for in vitro and in vivo applications, advancing therapeutic strategies targeting TLR/IL-1R signaling.